Catalyst Biosciences (Catalyst Biosciences) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Catalyst Biosciences Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Catalyst Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Catalyst Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.

Catalyst Biosciences Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Catalyst Biosciences's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Biosciences Short-Term Debt & Capital Lease Obligation Chart

Catalyst Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.48

0.66

1.98

0.04

Catalyst Biosciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.38	0.04	-	-	-

Catalyst Biosciences Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Catalyst Biosciences Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Catalyst Biosciences's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Biosciences (Catalyst Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Biosciences Inc (NAS:CBIO) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 710, South San Francisco, CA, USA, 94080

Website

https://www.catalystbiosciences.com

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Executives

Han Ying	director	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Charles C Wu	director, officer: Chief Executive Officer	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Songjiang Ma	director, officer: President	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Weiguo Ye	officer: Chief Operating Officer	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Renate Parry	director	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ruoyu Chen	officer: Interim CFO	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gordon Carmichael	director	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Gni Usa, Inc.	10 percent owner	12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Augustine Lawlor	director	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Andrea Hunt	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Seline E. Miller	officer: SVP Finance; Interim CFO & PAO	C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Gni Hong Kong Ltd	10 percent owner	12/F ELITE CENTRE, 22 HUNG TO ROAD, KWUN TONG KL K3 0000
Gni Group Ltd.	10 percent owner	NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023
Thomas Wilson Eastling	director	17520 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO CA 92130
Ying Luo	director	NIHONBASHI-HONCHO YS BLDG 3F, 2-2-2 NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-0023